Aliases & Classifications for Raynaud Disease

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 12 42 14 69
Raynaud's Disease 12 41
Raynaud's Syndrome [ambiguous] 12
Secondary Raynaud's Phenomenon 69
Raynaud's Syndrome Nos 12
Raynaud's Syndrome 12
Raynaud Phenomenon 69
Raynauds Syndrome 52



raynaud disease:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:10300
ICD10 33 I73.0
MeSH 42 D011928
SNOMED-CT via HPO 65 263681008
UMLS 69 C0034734

Summaries for Raynaud Disease

MedlinePlus : 41 raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. it causes the blood vessels to narrow when you are cold or feeling stressed. when this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. when the blood flow returns, the skin turns red and throbs or tingles. in severe cases, loss of blood flow can cause sores or tissue death. primary raynaud's happens on its own. the cause is not known. there is also secondary raynaud's, which is caused by injuries, other diseases, or certain medicines. people in colder climates are more likely to develop raynaud's. it is also more common in women, people with a family history, and those over age 30. treatment for raynaud's may include drugs to keep the blood vessels open. there are also simple things you can do yourself, such as soaking hands in warm water at the first sign of an attack keeping your hands and feet warm in cold weather avoiding triggers, such as certain medicines and stress nih: national heart, lung, and blood institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to reynolds syndrome and periodic limb movement disorder, and has symptoms including abnormality of the skeletal system, abdominal pain and angina pectoris. An important gene associated with Raynaud Disease is EDN1 (Endothelin 1), and among its related pathways/superpathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and Interleukin-10 signaling. The drugs Cilostazol and Platelet Aggregation Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and skin, and related phenotypes are homeostasis/metabolism and mortality/aging

Wikipedia : 72 Raynaud syndrome, also known as Raynaud\'s phenomenon, is a medical condition in which spasm of arteries... more...

Related Diseases for Raynaud Disease

Graphical network of the top 20 diseases related to Raynaud Disease:

Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Human phenotypes related to Raynaud Disease:

id Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924

UMLS symptoms related to Raynaud Disease:

abdominal pain, angina pectoris, chest pain, cold intolerance, constipation, coughing, diarrhea, dyspepsia, edema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, vertigo/dizziness, gastrointestinal gas, symptoms, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.5 ACOT7 CHST8 EDN1 FPR1 IL1R1 PTGIR
2 mortality/aging MP:0010768 9.17 VWF CENPB EDN1 FPR1 IL1R1 PTGIR

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Cilostazol Approved Phase 4 73963-72-1 2754
2 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
3 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 Anti-Asthmatic Agents Phase 4
5 Autonomic Agents Phase 4,Early Phase 1
6 Bronchodilator Agents Phase 4
7 Fibrinolytic Agents Phase 4
8 Neuroprotective Agents Phase 4,Early Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
10 Phosphodiesterase 3 Inhibitors Phase 4
11 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
12 Protective Agents Phase 4,Early Phase 1
13 Respiratory System Agents Phase 4
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
Tadalafil Approved, Investigational Phase 3,Phase 2 171596-29-5 110635
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
Nifedipine Approved Phase 3,Early Phase 1 21829-25-4 4485
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
22 Fasudil Investigational Phase 3 103745-39-7
23 Pharmaceutical Solutions Phase 3,Phase 2,Early Phase 1
24 Antihypertensive Agents Phase 2, Phase 3,Early Phase 1
25 Anesthetics Phase 2, Phase 3
26 abobotulinumtoxinA Phase 3,Phase 2
27 Botulinum Toxins Phase 3,Phase 2
28 Botulinum Toxins, Type A Phase 3,Phase 2
29 Cholinergic Agents Phase 3,Phase 2
30 insulin Phase 3
31 Insulin, Globin Zinc Phase 3
32 Neuromuscular Agents Phase 3,Phase 2
33 Neurotransmitter Agents Phase 3,Phase 2
34 onabotulinumtoxinA Phase 3,Phase 2
35 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3, Early Phase 1
36 Vardenafil Dihydrochloride Phase 2, Phase 3
Serotonin Phase 3 50-67-9 5202
38 calcium channel blockers Phase 3,Phase 2,Early Phase 1
39 Calcium, Dietary Phase 3,Phase 2,Early Phase 1
40 Tocolytic Agents Phase 3,Early Phase 1
41 Sildenafil Citrate Phase 2, Phase 3, Early Phase 1 171599-83-0
42 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine Phase 3
43 Protein Kinase Inhibitors Phase 3
44 Anticoagulants Phase 3
45 Chelating Agents Phase 3
46 Anesthetics, Local Phase 2, Phase 3
47 Central Nervous System Depressants Phase 2, Phase 3
St. John's Wort Nutraceutical Phase 3 84082-80-4
49 Citrate Nutraceutical Phase 2, Phase 3, Early Phase 1
Citric Acid Nutraceutical, Vet_approved Phase 2, Phase 3, Early Phase 1 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 65)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
3 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
4 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
5 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
6 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
7 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
8 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
9 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
11 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
12 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
13 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
14 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
15 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
16 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
17 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
18 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
19 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
20 Exparel as a Nerve Block for Severe Hand Pain Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
21 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
22 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Unknown status NCT02290613 Phase 2 Ambrisentan;Placebo
23 Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Completed NCT00528242 Phase 2 SLx-2101;Placebo
24 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
25 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
26 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
27 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
28 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
29 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2 Alprostadil
30 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
31 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2 Cialis
32 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
33 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
34 CSL Behring Sclero XIII Recruiting NCT02551042 Phase 2 Fibrogammin®P, coagulation factor XIII concentrate (Human);0.9% sodium chloride
35 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Active, not recruiting NCT01309802 Phase 2 onabotulinum toxin type-A
36 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
37 Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
38 MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
39 Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands Unknown status NCT01378845 Tracleer;Prostavasin
40 Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient Unknown status NCT00324181
41 Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft Unknown status NCT01133730 Active treatment;Placebo Arm
42 Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. Completed NCT02615964
43 Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis Completed NCT02212249
44 Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Completed NCT02683408
45 Botulinum Toxin in the Treatment of Raynaud's Completed NCT01233999 botulinum toxin A
46 Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis. Completed NCT01743612
47 Tadalafil for the Treatment of Raynaud's Completed NCT00822354 Tadalafil
48 Acupressure for the Treatment of Raynaud's Phenomenon Completed NCT01784354
49 ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease Completed NCT01064206
50 Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud Completed NCT03027674 Early Phase 1 10% nifedipine cream;5% sildenafil cream

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Cochrane evidence based reviews: raynaud disease

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

Lung, Heart, Skin, Endothelial, Bone

Publications for Raynaud Disease

Articles related to Raynaud Disease:

id Title Authors Year
Raynaud disease. ( 24211176 )
Intraoral telangiectasias associated with Raynaud disease: a report of two cases. ( 19907728 )
Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. ( 18627700 )
Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. ( 17532934 )
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. ( 16432094 )
Diabetes mellitus vs. Raynaud disease: different lung vascular bed disorders. ( 12505097 )
Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. ( 1586109 )
Effect of indoramin on finger circulation in patients with Raynaud disease. ( 2423806 )
Raynaud disease with oral manifestations. ( 1119826 )

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.96 PTGIR VWF
2 10.85 FPR1 IL1R1
3 10.49 EDN1 PTGIR
4 10.1 EDN1 PTGIR

GO Terms for Raynaud Disease

Cellular components related to Raynaud Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Weibel-Palade body GO:0033093 8.62 EDN1 VWF

Sources for Raynaud Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....